公开(公告)号：US20220087983A1

公开(公告)日：2022-03-24

申请号：US17477751

申请日：2021-09-17

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  David R. Lancia, JR. ,  Gary Marshall ,  Lorna Mitchell ,  David Richard ,  Zhongguo Wang ,  Sanjeev Forsyth ,  Patrick F. Kelly ,  Madhu Mondal ,  Maria Ribadeneira ,  Patricia Schroeder

IPC: A61K31/436 ,  A61P7/00

Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

公开(公告)号：US11071725B2

公开(公告)日：2021-07-27

申请号：US15929436

申请日：2020-05-01

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  David R. Lancia, Jr. ,  Gary Marshall ,  Lorna Mitchell ,  David Richard ,  Zhongguo Wang

IPC: A61K31/436 ,  A61P7/06 ,  A61K9/00 ,  C07D487/04

Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.

公开(公告)号：US11014927B2

公开(公告)日：2021-05-25

申请号：US16496279

申请日：2018-03-20

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  Bingsong Han ,  David R. Lancia, Jr. ,  Lorna Mitchell ,  David Richard ,  Tatiana Shelekhin ,  Chase C. Smith ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D487/04 ,  C07D519/00 ,  A61P7/00 ,  A61K9/00 ,  A61K31/407

Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

公开(公告)号：US10807976B2

公开(公告)日：2020-10-20

申请号：US16517866

申请日：2019-07-22

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  A61P35/00

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.

公开(公告)号：US20200223822A1

公开(公告)日：2020-07-16

申请号：US16712951

申请日：2019-12-12

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  A61P35/00 ,  C07D471/04 ,  C07D401/14

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US20200085798A1

公开(公告)日：2020-03-19

申请号：US16576360

申请日：2019-09-19

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  David R. Lancia, JR. ,  Gary Marshall ,  Lorna Mitchell ,  David Richard ,  Zhongguo Wang

IPC: A61K31/436

Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.

公开(公告)号：US20200017525A1

公开(公告)日：2020-01-16

申请号：US16077407

申请日：2017-02-13

Applicant: FORMA Therapeutics, Inc.

Inventor： David Joseph Guerin ,  Kenneth W. Bair ,  Justin A. Caravella ,  Stephanos Ioannidis, Jr. ,  David R. Lancia, Jr. ,  Hongbin Li ,  Steven Mischke ,  Pui Yee Ng ,  David Richard ,  Shawn E.R. Schiller ,  Tatiana Shelekhin ,  Zhongguo Wang

IPC: C07D519/00 ,  C07D495/04

Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, R7, X, m, and n are described herein.

公开(公告)号：US20200010464A1

公开(公告)日：2020-01-09

申请号：US16517866

申请日：2019-07-22

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  A61P35/00

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.

公开(公告)号：US10399980B2

公开(公告)日：2019-09-03

申请号：US16051879

申请日：2018-08-01

Applicant: FORMA Therapeutics, Inc.

Inventor： Alexandre Joseph Buckmelter ,  Stephanos Ioannidis ,  Bruce Follows ,  Gary Gustafson ,  Minghua Wang ,  Justin A. Caravella ,  Zhongguo Wang ,  Edward L. Fritzen ,  Jian Lin

IPC: C07D473/00 ,  A61K31/522

Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3′, R4, R5, X1, X2, X3, X4, and n are described herein.

公开(公告)号：US20190263779A1

公开(公告)日：2019-08-29

申请号：US16290328

申请日：2019-03-01

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D403/12 ,  C07D409/14 ,  C07D471/04 ,  C07D405/14 ,  C07D417/14 ,  C07D401/14 ,  C07D413/14

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.